Advancing a Neutral Antagonist of the CB1 Receptor in Preclinical Development for Alcohol, Opioid & Cocaine Use Disorders
Time: 11:30 am
day: Conference Day 1
Details:
- Looking at how AM6527, a neutral CB1 receptor antagonist, effectively inhibits heroin and cocaine self-administration under progressive-ratio reinforcement schedules in addiction models
- Discussing behavioural effects and tolerance development in preclinical findings
- Analyzing safety profile and future directions, comparing to Rimonabant suggests it may offer a safer alternative for treating substance use disorders
